11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Sevelamer 2care4

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Sevelamer

Sevelamer

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Svenskt njurregister årsrapport 2018. Svenskt njurregister [www]. [cited 2019-05-23].

  2. Ho LT, Sprague SM. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013;20(5):423-6.

  3. Hecking M, Bieber BA, Ethier J, Kautzky-Willer A, Sunder-Plassmann G, Säemann MD et al. Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med. 2014;11(10):e1001750.

  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - RENAGEL (sevelamer hydrochloride). US Food and Drug Administration [www]. [updated 2005-07-01, cited 2019-05-23].

  5. Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol. 2000;54(4):334-41.

  6. Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. 2019;1(1):1.

  7. Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, AGE-less Study Group. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol. 2015;10(5):759-66.

  8. Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant. 2006;21(2):459-65.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]

  1. Svenskt njurregister årsrapport 2018. Svenskt njurregister [www]. [cited 2019-05-23].
  2. Ho LT, Sprague SM. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013;20(5):423-6.
  3. Hecking M, Bieber BA, Ethier J, Kautzky-Willer A, Sunder-Plassmann G, Säemann MD et al. Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med. 2014;11(10):e1001750.
  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - RENAGEL (sevelamer hydrochloride). US Food and Drug Administration [www]. [updated 2005-07-01, cited 2019-05-23].
  5. Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol. 2000;54(4):334-41.
  6. Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. 2019;1(1):1.
  7. Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, AGE-less Study Group. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol. 2015;10(5):759-66.
  8. Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant. 2006;21(2):459-65.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]